YR0008

Leader in Biomolecular Solutions for Life Science

www.abclonal.com

Human VEGF Monoclonal Antibody

Catalog No.: YR0008

Basic Information

Molecular Weight
150 kDa

Endotoxin
<1EU/mg (<0.001EU/μg)Determined by LAL gel clotting assay

Sterility
0.2 μm filtration

Aggregation
<5% Determined by SECP

Purity
>95% Determined by SEC-HPLC

Background

Bevacizumab, the humanized anti-VEGF-A monoclonal antibody, produces angiogenesis inhibition and slows the growth of new blood vessels. As the first clinically available angiogenesis inhibitor in the United States, Bevacizumab is used for treatment of certain metastatic cancers, certain lung cancers, renal cancers, ovarian cancers, breast cancers, and glioblastoma multiforme of the brain.Vascular endothelial growth factor A (VEGF-A) stimulates angiogenesis in a variety of cancers, including colorectal, lung, breast, glioblastoma, kidney, and ovarian cancers.

Reported Applications

ELISA,neutralization,functional assays such as bioanalytical PK and ADA assays,and those assays for studying biological pathways

Immunogen Information

Clone
Bevacizumab Biosimilar

Isotype
Human IgG1 kappa

Immunogen
Human VGEF

RecommendedIsotype Control(s)
In Vivo Grade Recombinant Human IgG1 Kappa Isotype Control Antibody

Recommended Dilution Buffer
1×PBS pH 7.3

Contact

www.abclonal.com

Product Information

Production
Purified from cell culture supernatant in an animal-free facility

Purification
Protein A or G purification

Storage
Store at 2 - 8℃. 2 - 8°C for up to 4 weeks and -80°C for long term storage (Avoid repeated freezing and thawing)

Validation Data



Direct ELISA binding curve demonstrating the recognition of Human Anti-Human VEGF (Research Grade Bevacizumab Biosimilar) Monoclonal Antibody to VEGF. The target protein was coated onto the microplate well surface, followed by binding of the antibody. A donkey anti-human IgG HRP conjugate was used for detection.



Through SPR measurement, the human anti-human VEGF-A (Research Grade Bevacizumab Biosimila) monoclonal antibody is capable of binding to human VEGF-A with an affinity greater than 1pM.